Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma informed exchanges about a High Court of Telangana order dated May 6, 2026, which dismissed a writ petition filed by promoter group members. These members (Mr. P.V. Ramprasad Reddy, Ms. P. Suneela Rani, Mr. Kambam Prasad Reddy, and Trident Chemphar Limited) had challenged a SEBI communication directing them to deposit Rs. 6.53 crores in profits (made from trading in Aurobindo Pharma shares) along with 12% interest per annum into SEBI's Investor Protection Fund. The case stems from alleged insider trading violations under SEBI's PIT Regulations, 1992. The petitioners settled with SEBI in May 2020, but later disputed the profit-sharing demand. The company states the order is against the Petitioners and has no impact on the company's financials or operations.
The ruling is a setback for the promoter group members who must now comply with the SEBI directive. Since this involves promoters personally and not the company, there should be no direct financial impact on Aurobindo Pharma, though it highlights ongoing regulatory scrutiny on insider trading matters.